Financials in USD. Standardized financial statements.
A compact view of how Zhong Yuan Bio-Technology Holdings Limited turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.28M | $1.66M | $2.33M | $1.64M | $1.22M | $1.22M | $0 | $0 |
| Revenue Growth? | +37.0% | -28.6% | +42.4% | +34.1% | +0.2% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $206,374 | $144,683 | $420,273 | $281,962 | $257,034 | $320,836 | $0 | $0 |
| Gross Profit? | $2.07M | $1.52M | $1.91M | $1.35M | $962,616 | $896,752 | $0 | $0 |
| Gross Margin? | +90.9% | +91.3% | +82.0% | +82.8% | +78.9% | +73.6% | 0.0% | 0.0% |
| Operating Expenses? | $1.81M | $2.77M | $2.59M | $1.37M | $1.05M | $584,616 | $27,191 | $2,749 |
| Operating Income? | $266,557 | -$1.25M | -$685,759 | -$14,595 | -$85,509 | $312,136 | -$27,191 | -$2,749 |
| EBITDA? | $475,119 | -$1.47M | -$452,931 | $178,997 | -$61,606 | $322,094 | $0 | $0 |
| Income Before Tax | $271,275 | -$1.76M | -$671,544 | -$28,022 | -$87,299 | $296,095 | -$27,191 | -$2,749 |
| Income Tax Expense | -$594 | -$8,840 | $11,119 | $0 | $0 | $15,912 | $0 | $0 |
| Net Income? | $302,210 | -$2.23M | -$1.13M | -$28,022 | -$87,299 | $280,183 | -$27,191 | -$2,749 |
| EPS? | $0.02 | $-0.12 | $-0.07 | $-0.00 | $-0.01 | $0.01 | $-0.00 | $-0.00 |
| Diluted EPS? | $0.02 | $-0.12 | $-0.07 | $-0.00 | $-0.01 | $0.01 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality